Each step. Every patient. Exactly what you need.
Schedule a meeting with us
ASCO 2025 is right around the corner, and we would love to connect with you at the Annual Meeting. Visit Myriad Oncology at Booth #25031 to discover our full portfolio of germline and tumor genomic tests, including our comprehensive suite of services and workflow solutions designed to support you and your patients at each step of the care journey.
We look forward to seeing you in Chicago!
Abstract #:
3007
Session:
Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology
Date:
5/30/2025
Time:
2:45-5:45PM CDT
Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: Initial results from the MONSTAR-SCREEN-3 project Tadayoshi Hashimoto, MD, PhD
Research outcomes: Updated molecular and clinical outcome data to be presented based on interim results demonstrating successful pan-cancer implementation of WGS-based personalized ctDNA detection, achieving universal baseline sensitivity and ultra-sensitive MRD detection across tumor types, including those traditionally challenging to assess.
10500
Prevention, Risk Reduction, and Genetics
6/2/2025
11:30AM-2:30PM CDT
Sensitivity of age and family history criteria for pancreatic cancer surveillance (PCS) prioritization among carriers of monogenic predisposition to pancreatic cancer (PC) Asaf Maoz, MD
Research outcomes: FH has poor sensitivity in identifying PC among individuals with a monogenic predisposition to PC. Validation of these findings in an unselected clinic-based cohort is ongoing and requires further research to identify risk factors that can be used to prioritize PC surveillance among these individuals.
10512
5/31/2025
8:00-9:30AM CDT
Interactions between polygenic variants and clinical factors as predictors of breast cancer risk in the UK Biobank (UKB) Sandhya Pruthi, MD
Research outcomes: In a longitudinal analysis of UKB, MA-385 was a highly significant predictor of breast cancer (BC) and substantially improved prediction over TC. In contrast, interactions of MA-385, and individual BC SNPs, with TC and individual clinical factors in the TC model were not statistically significant. Clinical TC factors have minimal, if any, impact on the strength of the association between MA-385 and BC, helping to alleviate concerns expressed in guidelines that SNPs interact with environmental or hormonal risk factors.
10513
Associations of an ancestry-specific variant near the ESR1 gene with cancer risk and breast density in women of self-reported Hispanic ancestry Allison Kurian, MD, FASCO, MSc, MS
Research outcomes: Findings from the largest study to date on cancer risks associated with rs140068132 indicate that rs140068132 does not substantially affect the risk of ovarian cancer (OC) or EC. Previous reports confirmed of significantly reduced risk of BC, particularly TNBC, among carriers of rs140068132 with precise estimates of the ORs per allele, indicating important implications for genetic risk assessment and may guide personalized BC prevention and treatment strategies.
Poster Board:
302
10577
1:30-4:30PM CDT
Estimated prevalence of pathogenic variants in patients with breast, colon, and/or endometrial cancer who do not meet guidelines for genetic testing Elisha Hughes, PhD
Research outcomes: Results support existing literature that a substantial fraction of patients who do not meet guidelines for genetic testing may carry PVs, including a high prevalence of PVs among endometrial cancer (EC) patients without FH, regardless of age at diagnosis. Elimination of age-based restrictions on genetic testing could improve the survival of cancer patients and their family members.
52
1073
Breast Cancer - Metastatic
9:00AM-12:00PM CDT
Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer Julia Ah-Reum An, MD, MPH
Research outcomes: Ultrasensitive ctDNA monitoring is a promising tool for monitoring disease burden and treatment response. Our results highlight the ability of ctDNA to distinguish between stable molecular disease vs. mCR, highlighting the potential of ctDNA as a biomarker for tailoring treatment strategies in patients who achieve outstanding clinical responses.
311
10586
1:30PM-4:30PM CDT
Incidence of concurrent pathogenic variants in BRCA1 breast cancer patients Katelynn Cai
Research outcomes: It is well established that certain deleterious genes significantly increase the risk of specific cancers, showing the importance of evaluating patients for additional gene mutations. Without the capability to expand genetic testing panels, there is a risk of overlooking potential cancer predispositions in patients who may have an elevated risk for other malignancies.
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information